Related Experiment Video
Updated: May 15, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART
Kirusha Naidoo1, Richard J Lessells1,2, Jienchi Dorward1,3
1Department of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Abstract:
The integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance within 3 months, while receiving rifapentine-based tuberculosis preventive therapy.
Related Concept Videos
Retrovirus Life Cycles
Treatment Resistant Cancers
Viral Mutations
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

